In the original article [1], there were two mistakes in the published version of Table 1. For patient 3, the tumor should be “Metastasis” instead of “Primary”; for patient 10, the excision place should be “Lymph Node” instead of “Skin”. The corrected Table 1 appears below.
Table 1.
Gender | Tumor | Excision Place | Cell Lines | Treatment | Immunotherapy | Duration | Cell Line Purity | |
---|---|---|---|---|---|---|---|---|
Patient 1 | M | Metastasis | Lymph node | MM130820 | Before IT | 87% | ||
Patient 2 | F | Metastasis | Trunk | MM150325 | Before IT | 98% | ||
F | Metastasis | Trunk | MM150604 | Relapsed | Ipilimumab | 3 weeks | 74% | |
Patient 3 | F | Metastasis | Lymph node | MM140905 | Before IT | 99% | ||
Patient 4 | M | Metastasis | Back | M130107 | Before IT | 59% | ||
M | Metastasis | Lymph node | M121102 | Before IT | 65% | |||
Patient 5 | F | Metastasis | Lung | M121008 | Before IT | 20% | ||
Patient 6 | F | Metastasis | Lymph node | MM130626 | Before IT | 60% | ||
Patient 7 | F | Metastasis | Leg | MM130106 | Before IT | 57% | ||
F | Metastasis | Leg | MM131205 | Relapsed | Ipilimumab | 3 weeks | 78% | |
F | Metastasis | Leg | MM131206 | Relapsed | Ipilimumab | 3 weeks | 65% | |
Patient 8 | M | Metastasis | Trunk | MM150405 | Before IT | 58% | ||
M | Metastasis | Lymph node | M150404 | Before IT | ||||
Patient 9 | F | Metastasis | Skin | MM130926 | Before IT | 50% | ||
Patient 10 | F | Metastasis | Lymph node | M980513 | Before IT | 83% | ||
Patient 11 | M | Metastasis | Arm | MM140902 | Relapsed | Ipilimumab | 3 months | 100% |
M | Metastasis | Arm | M130830 | Relapsed | Ipilimumab | 3 months | 100% | |
Patient 12 | M | Metastasis | Back | MM130434 | Relapsed | Ipilimumab | 3 months | 77% |
Patient 13 | M | Metastasis | Trunk | MM121224 | Relapsed | Ipilimumab | 3 months | 75% |
Patient 14 | M | Metastasis | Skin | M130420 | Relapsed | Ipilimumab | 10 days | 100% |
M | Metastasis | Liver | M130421 | Relapsed | Ipilimumab | 10 days | 100% | |
M | Metastasis | Testis | M130425 | Relapsed | Ipilimumab | 10 days | 100% | |
M | Metastasis | Lung | MM130427 | Relapsed | Ipilimumab | 10 days | 97% |
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reference
- 1.Tusup M., Cheng P.F., Picardi E., Raziunaite A., Dummer R., Levesque M.P., French L.E., Guenova E., Kundig T.M., Pascolo S. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA. 2021;7:5. doi: 10.3390/ncrna7010005. [DOI] [PMC free article] [PubMed] [Google Scholar]